DiaMedica Therapeutics (DMAC) Enterprise Value (2017 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Enterprise Value of -$51.3 million for Q1 2026, down 1740.48% year-over-year from $3.1 million in Q1 2025, and up 14.29% quarter-over-quarter from -$59.9 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Enterprise Value (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$51.3 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 1740.48% year-over-year to -$51.3 million; the TTM figure through Mar 2026 stood at -$51.3 million (down 1740.48% YoY), while the FY2025 annual figure was -$59.9 million, down 35.66% from the prior year.
- Enterprise Value for Q1 2026 stood at -$51.3 million, up from -$59.9 million in the prior quarter.
- The five-year high for Enterprise Value was -$2.8 million in Q3 2022, with the low at -$59.9 million in Q4 2025.
- The 5-year median for Enterprise Value is -$44.1 million (2024), against an average of -$36.2 million.
- The sharpest annual moves came in 2022 and 2026: Enterprise Value surged 94.22% in 2022, then slumped 1740.48% in 2026.
- DiaMedica Therapeutics' Enterprise Value stood at -$33.5 million in 2022, then sank by 57.89% to -$52.9 million in 2023, then gained by 16.54% to -$44.1 million in 2024, then sank by 35.66% to -$59.9 million in 2025, then climbed by 14.29% to -$51.3 million in 2026.
- Business Quant data shows DMAC's Enterprise Value at -$51.3 million in Q1 2026, -$59.9 million in Q4 2025, and -$55.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -43.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.50 Mn |
| Mar 31, 2026 | -51.33 Mn |
| Dec 31, 2025 | -59.89 Mn |
| Sep 30, 2025 | -55.32 Mn |
| Jun 30, 2025 | -4.31 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -44.15 Mn |
| Sep 30, 2024 | -50.20 Mn |
| Jun 30, 2024 | -54.06 Mn |
| Mar 31, 2024 | -46.52 Mn |
| Dec 31, 2023 | -52.90 Mn |
| Sep 30, 2023 | -46.47 Mn |
| Jun 30, 2023 | -40.37 Mn |
| Mar 31, 2023 | -28.66 Mn |
| Dec 31, 2022 | -33.50 Mn |
| Sep 30, 2022 | -2.78 Mn |
| Jun 30, 2022 | -38.44 Mn |
| Mar 31, 2022 | -3.14 Mn |
| Dec 31, 2021 | -45.11 Mn |
| Sep 30, 2021 | -48.10 Mn |